{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:05:50Z","timestamp":1791255950042,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytarabine (Ara-C) is the first-line drug for the treatment of acute myelogenous leukemia (AML). However, resistance eventually develops, decreasing the efficacy of Ara-C in AML patients. The expression of SAMHD1, a deoxynucleoside triphosphate (dNTP) triphosphohydrolase, has been reported to be elevated in Ara-C-resistant AML patients and to play a crucial role in mediating Ara-C resistance in AML. However, the mechanism by which SAMHD1 is upregulated in resistant AML remains unknown. In this study, NONO interacted with and stabilized SAMHD1 by inhibiting DCAF1-mediated ubiquitination\/degradation of SAMHD1. Overexpression of NONO increased SAMHD1 expression and reduced the sensitivity of AML cells to Ara-C, and downregulation of NONO had the opposite effects. In addition, the DNA-damaging agents DDP and adriamycin (ADM) reduced NONO\/SAMHD1 expression and sensitized AML cells to Ara-C. More importantly, NONO was upregulated in Ara-C-resistant AML cells, resulting in increased SAMHD1 expression in resistant AML cells, and DDP and ADM treatment resensitized resistant AML cells to Ara-C. This study revealed the mechanism by which SAMHD1 is upregulated in Ara-C-resistant AML cells and provided novel therapeutic strategies for Ara-C-resistant AML.<\/jats:p>","DOI":"10.1038\/s41419-022-05023-0","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T12:04:10Z","timestamp":1657281850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8654-1849","authenticated-orcid":false,"given":"Feifei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanhui","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzai","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3993-974X","authenticated-orcid":false,"given":"Haiyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7641-3421","authenticated-orcid":false,"given":"Changhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3970-1117","authenticated-orcid":false,"given":"Xiao-Bin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"key":"5023_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","volume":"125","author":"G Ossenkoppele","year":"2015","unstructured":"Ossenkoppele G, Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood 2015;125:767\u201374.","journal-title":"Blood"},{"key":"5023_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-07-657403","volume":"127","author":"MR Luskin","year":"2016","unstructured":"Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 2016;127:1551\u20138.","journal-title":"Blood"},{"key":"5023_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl J Med. 2009;361:1249\u201359.","journal-title":"N. Engl J Med"},{"key":"5023_CR4","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2217\/pgs.09.118","volume":"10","author":"JK Lamba","year":"2009","unstructured":"Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 2009;10:1657\u201374.","journal-title":"Pharmacogenomics"},{"key":"5023_CR5","first-page":"269","volume":"14","author":"R Zittoun","year":"1987","unstructured":"Zittoun R, Marie JP, Delanian S, Suberville AM, Thevenin D. Prognostic value of in vitro uptake and retention of cytosine arabinoside in acute myelogenous leukemia. Semin Oncol. 1987;14:269\u201375.","journal-title":"Semin Oncol"},{"key":"5023_CR6","first-page":"580","volume":"1","author":"E Estey","year":"1987","unstructured":"Estey E, Plunkett W, Dixon D, Keating M, McCredie K, Freireich EJ. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;1:580\u20133.","journal-title":"Leukemia"},{"key":"5023_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10:506\u201325.","journal-title":"Cancer Discov"},{"key":"5023_CR8","doi-asserted-by":"publisher","first-page":"103441","DOI":"10.1016\/j.ebiom.2021.103441","volume":"69","author":"Q Ling","year":"2021","unstructured":"Ling Q, Li F, Zhang X, Mao S, Lin X, Pan J, et al. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage\/repair system and MAPK pathway. EBioMedicine 2021;69:103441.","journal-title":"EBioMedicine"},{"key":"5023_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nm.4255","volume":"23","author":"C Schneider","year":"2017","unstructured":"Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23:250\u20135.","journal-title":"Nat Med"},{"key":"5023_CR10","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nm.4265","volume":"23","author":"N Herold","year":"2017","unstructured":"Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, et al. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med. 2017;23:256\u201363.","journal-title":"Nat Med"},{"key":"5023_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1080\/15384101.2018.1480218","volume":"17","author":"KM Kodigepalli","year":"2018","unstructured":"Kodigepalli KM, Bonifati S, Tirumuru N, Wu L. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle. 2018;17:1124\u201337.","journal-title":"Cell Cycle"},{"key":"5023_CR12","first-page":"331","volume":"171","author":"H Fanta","year":"1977","unstructured":"Fanta H. [Cataract extraction after a fistulizing operation (author\u2019s transl)]. Klin Monbl Augenheilkd. 1977;171:331\u20137.","journal-title":"Klin Monbl Augenheilkd"},{"key":"5023_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41586-018-0050-1","volume":"557","author":"F Coquel","year":"2018","unstructured":"Coquel F, Silva MJ, Techer H, Zadorozhny K, Sharma S, Nieminuszczy J, et al. SAMHD1 acts at stalled replication forks to prevent interferon induction. Nature 2018;557:57\u201361.","journal-title":"Nature"},{"key":"5023_CR14","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.celrep.2017.08.008","volume":"20","author":"W Daddacha","year":"2017","unstructured":"Daddacha W, Koyen AE, Bastien AJ, Head PE, Dhere VR, Nabeta GN, et al. SAMHD1 promotes DNA End Resection to Facilitate DNA Repair by Homologous Recombination. Cell Rep. 2017;20:1921\u201335.","journal-title":"Cell Rep"},{"key":"5023_CR15","doi-asserted-by":"publisher","first-page":"5084.","DOI":"10.3390\/ijms21145084","volume":"21","author":"F Freisleben","year":"2020","unstructured":"Freisleben F, Behrmann L, Thaden V, Muschhammer J, Bokemeyer C, Fiedler W, et al. Downregulation of GLI3 expression mediates chemotherapy resistance in acute myeloid leukemia. Int J Mol Sci. 2020;21:5084.","journal-title":"Int J Mol Sci"},{"key":"5023_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.21037\/jtd-20-1889","volume":"13","author":"Y Wu","year":"2021","unstructured":"Wu Y, Niu Y, Wu Y, Chen X, Shen X, Gao W. SAMHD1 can suppress lung adenocarcinoma progression through the negative regulation of STING. J Thorac Dis. 2021;13:189\u2013201.","journal-title":"J Thorac Dis"},{"key":"5023_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/15384101.2017.1314407","volume":"16","author":"N Herold","year":"2017","unstructured":"Herold N, Rudd SG, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, et al. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell Cycle. 2017;16:1029\u201338.","journal-title":"Cell Cycle"},{"key":"5023_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11413-4","volume":"10","author":"T Oellerich","year":"2019","unstructured":"Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, et al. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. Nat Commun. 2019;10:3475.","journal-title":"Nat Commun"},{"key":"5023_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0165-2478(00)00276-5","volume":"74","author":"N Li","year":"2000","unstructured":"Li N, Zhang W, Cao X. Identification of human homologue of mouse IFN-gamma induced protein from human dendritic cells. Immunol Lett. 2000;74:221\u20134.","journal-title":"Immunol Lett"},{"key":"5023_CR20","doi-asserted-by":"publisher","first-page":"9284","DOI":"10.1074\/jbc.M112.447201","volume":"288","author":"S de Silva","year":"2013","unstructured":"de Silva S, Hoy H, Hake TS, Wong HK, Porcu P, Wu L. Promoter methylation regulates SAMHD1 gene expression in human CD4+ T cells. J Biol Chem. 2013;288:9284\u201392.","journal-title":"J Biol Chem"},{"key":"5023_CR21","doi-asserted-by":"publisher","first-page":"11516","DOI":"10.1128\/JVI.01642-13","volume":"87","author":"S Welbourn","year":"2013","unstructured":"Welbourn S, Dutta SM, Semmes OJ, Strebel K. Restriction of virus infection but not catalytic dNTPase activity is regulated by phosphorylation of SAMHD1. J Virol. 2013;87:11516\u201324.","journal-title":"J Virol"},{"key":"5023_CR22","doi-asserted-by":"publisher","first-page":"68517","DOI":"10.18632\/oncotarget.19704","volume":"8","author":"EJ Lee","year":"2017","unstructured":"Lee EJ, Seo JH, Park JH, Vo TTL, An S, Bae SJ, et al. SAMHD1 acetylation enhances its deoxynucleotide triphosphohydrolase activity and promotes cancer cell proliferation. Oncotarget 2017;8:68517\u201329.","journal-title":"Oncotarget"},{"key":"5023_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24802-5","volume":"12","author":"C Martinat","year":"2021","unstructured":"Martinat C, Cormier A, Tobaly-Tapiero J, Palmic N, Casartelli N, Mahboubi B, et al. SUMOylation of SAMHD1 at Lysine 595 is required for HIV-1 restriction in non-cycling cells. Nat Commun. 2021;12:4582.","journal-title":"Nat Commun"},{"key":"5023_CR24","doi-asserted-by":"crossref","first-page":"e47528","DOI":"10.15252\/embr.201847528","volume":"21","author":"Z Li","year":"2020","unstructured":"Li Z, Huan C, Wang H, Liu Y, Liu X, Su X, et al. TRIM21-mediated proteasomal degradation of SAMHD1 regulates its antiviral activity. EMBO Rep. 2020;21:e47528.","journal-title":"EMBO Rep"},{"key":"5023_CR25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.coviro.2012.09.010","volume":"2","author":"B Romani","year":"2012","unstructured":"Romani B, Cohen EA. Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase. Curr Opin Virol. 2012;2:755\u201363.","journal-title":"Curr Opin Virol"},{"key":"5023_CR26","doi-asserted-by":"publisher","first-page":"6746","DOI":"10.1093\/nar\/gkp741","volume":"37","author":"S Li","year":"2009","unstructured":"Li S, Kuhne WW, Kulharya A, Hudson FZ, Ha K, Cao Z, et al. Involvement of p54(nrb), a PSF partner protein, in DNA double-strand break repair and radioresistance. Nucleic Acids Res. 2009;37:6746\u201353.","journal-title":"Nucleic Acids Res"},{"key":"5023_CR27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/onc.2014.96","volume":"34","author":"M Bonora","year":"2015","unstructured":"Bonora M, Wieckowski MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L, et al. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. Oncogene 2015;34:1475\u201386.","journal-title":"Oncogene"},{"key":"5023_CR28","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1016\/j.jid.2018.05.016","volume":"138","author":"L Yang","year":"2018","unstructured":"Yang L, Jin L, Ke Y, Fan X, Zhang T, Zhang C, et al. E3 ligase Trim21 ubiquitylates and stabilizes keratin 17 to induce STAT3 activation in psoriasis. J Invest Dermatol. 2018;138:2568\u201377.","journal-title":"J Invest Dermatol"},{"key":"5023_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9017","volume":"6","author":"C Yu","year":"2015","unstructured":"Yu C, Ji SY, Sha QQ, Sun QY, Fan HY. CRL4-DCAF1 ubiquitin E3 ligase directs protein phosphatase 2A degradation to control oocyte meiotic maturation. Nat Commun. 2015;6:8017.","journal-title":"Nat Commun"},{"key":"5023_CR30","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1038\/s41388-021-01834-1","volume":"40","author":"F Zhang","year":"2021","unstructured":"Zhang F, Tang X, Fan S, Liu X, Sun J, Ju C, et al. Targeting the p300\/NONO axis sensitizes melanoma cells to BRAF inhibitors. Oncogene 2021;40:4137\u201350.","journal-title":"Oncogene"},{"key":"5023_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/nar\/gky1166","volume":"47","author":"R Deshar","year":"2019","unstructured":"Deshar R, Yoo W, Cho EB, Kim S, Yoon JB. RNF8 mediates NONO degradation following UV-induced DNA damage to properly terminate ATR-CHK1 checkpoint signaling. Nucleic Acids Res. 2019;47:762\u201378.","journal-title":"Nucleic Acids Res"},{"key":"5023_CR32","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1111\/jcmm.15141","volume":"24","author":"P Feng","year":"2020","unstructured":"Feng P, Li L, Deng T, Liu Y, Ling N, Qiu S, et al. NONO and tumorigenesis: more than splicing. J Cell Mol Med. 2020;24:4368\u201376.","journal-title":"J Cell Mol Med"},{"key":"5023_CR33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2017.12.010","volume":"27","author":"G Benegiamo","year":"2018","unstructured":"Benegiamo G, Mure LS, Erikson G, Le HD, Moriggi E, Brown SA, et al. The RNA-binding protein NONO coordinates hepatic adaptation to feeding. Cell Metab. 2018;27:404\u201318.e7.","journal-title":"Cell Metab"},{"key":"5023_CR34","doi-asserted-by":"publisher","first-page":"7974","DOI":"10.7150\/thno.45037","volume":"10","author":"SJ Kim","year":"2020","unstructured":"Kim SJ, Ju JS, Kang MH, Eun JW, Kim YH, Raninga PV, et al. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. Theranostics. 2020;10:7974\u201392.","journal-title":"Theranostics"},{"key":"5023_CR35","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jcmm.16243","volume":"25","author":"P Feng","year":"2021","unstructured":"Feng P, Li L, Dai J, Zhou L, Liu J, Zhao J, et al. The regulation of NONO by USP11 via deubiquitination is linked to the proliferation of melanoma cells. J Cell Mol Med. 2021;25:1507\u201317.","journal-title":"J Cell Mol Med"},{"key":"5023_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ymthe.2020.08.018","volume":"29","author":"R Xie","year":"2021","unstructured":"Xie R, Chen X, Cheng L, Huang M, Zhou Q, Zhang J, et al. NONO inhibits lymphatic metastasis of bladder cancer via alternative splicing of SETMAR. Mol Ther. 2021;29:291\u2013307.","journal-title":"Mol Ther"},{"key":"5023_CR37","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41388-020-01617-0","volume":"40","author":"XK Yin","year":"2021","unstructured":"Yin XK, Wang YL, Wang F, Feng WX, Bai SM, Zhao WW, et al. PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer. Oncogene 2021;40:1375\u201389.","journal-title":"Oncogene"},{"key":"5023_CR38","doi-asserted-by":"publisher","first-page":"112148","DOI":"10.1016\/j.yexcr.2020.112148","volume":"394","author":"X Zhao","year":"2020","unstructured":"Zhao X, Bao M, Zhang F, Wang W. Camptothecin induced DDX5 degradation increased the camptothecin resistance of osteosarcoma. Exp Cell Res. 2020;394:112148.","journal-title":"Exp Cell Res"},{"key":"5023_CR39","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1128\/MCB.00993-14","volume":"35","author":"JY Lu","year":"2015","unstructured":"Lu JY, Sewer MB. p54nrb\/NONO regulates cyclic AMP-dependent glucocorticoid production by modulating phosphodiesterase mRNA splicing and degradation. Mol Cell Biol. 2015;35:1223\u201337.","journal-title":"Mol Cell Biol"},{"key":"5023_CR40","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/ncb1433","volume":"8","author":"X Wu","year":"2006","unstructured":"Wu X, Yoo Y, Okuhama NN, Tucker PW, Liu G, Guan JL. Regulation of RNA-polymerase-II-dependent transcription by N-WASP and its nuclear-binding partners. Nat Cell Biol. 2006;8:756\u201363.","journal-title":"Nat Cell Biol"},{"key":"5023_CR41","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/cas.14240","volume":"111","author":"K Iino","year":"2020","unstructured":"Iino K, Mitobe Y, Ikeda K, Takayama KI, Suzuki T, Kawabata H, et al. RNA-binding protein NONO promotes breast cancer proliferation by post-transcriptional regulation of SKP2 and E2F8. Cancer Sci. 2020;111:148\u201359.","journal-title":"Cancer Sci"},{"key":"5023_CR42","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.molcel.2009.06.027","volume":"35","author":"LL Chen","year":"2009","unstructured":"Chen LL, Carmichael GG. Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. Mol Cell. 2009;35:467\u201378.","journal-title":"Mol Cell"},{"key":"5023_CR43","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00018-019-03033-4","volume":"76","author":"HC de Silva","year":"2019","unstructured":"de Silva HC, Lin MZ, Phillips L, Martin JL, Baxter RC. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer. Cell Mol Life Sci. 2019;76:2015\u201330.","journal-title":"Cell Mol Life Sci"},{"key":"5023_CR44","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/hep.31062","volume":"72","author":"Z Hu","year":"2020","unstructured":"Hu Z, Dong L, Li S, Li Z, Qiao Y, Li Y, et al. Splicing regulator p54(nrb) \/Non-POU domain-containing octamer-binding protein enhances carcinogenesis through oncogenic isoform switch of MYC box-dependent interacting protein 1 in hepatocellular carcinoma. Hepatology 2020;72:548\u201368.","journal-title":"Hepatology"},{"key":"5023_CR45","doi-asserted-by":"publisher","first-page":"e10419","DOI":"10.15252\/emmm.201910419","volume":"12","author":"SG Rudd","year":"2020","unstructured":"Rudd SG, Tsesmetzis N, Sanjiv K, Paulin CB, Sandhow L, Kutzner J, et al. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. EMBO Mol Med. 2020;12:e10419.","journal-title":"EMBO Mol Med"},{"key":"5023_CR46","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/onc.2015.107","volume":"35","author":"L Alfano","year":"2016","unstructured":"Alfano L, Costa C, Caporaso A, Altieri A, Indovina P, Macaluso M, et al. NONO regulates the intra-S-phase checkpoint in response to UV radiation. Oncogene 2016;35:567\u201376.","journal-title":"Oncogene"},{"key":"5023_CR47","doi-asserted-by":"publisher","first-page":"78127","DOI":"10.18632\/oncotarget.13002","volume":"7","author":"L Alfano","year":"2016","unstructured":"Alfano L, Costa C, Caporaso A, Antonini D, Giordano A, Pentimalli F. HUR protects NONO from degradation by mir320, which is induced by p53 upon UV irradiation. Oncotarget. 2016;7:78127\u201339.","journal-title":"Oncotarget"},{"key":"5023_CR48","first-page":"99","volume":"42","author":"K Shimura","year":"2001","unstructured":"Shimura K, Shimazaki C, Okano A, Hatsuse M, Okamoto A, Takahashi R. et al. Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer. Rinsho Ketsueki. 2001;42:99\u2013103.","journal-title":"Rinsho Ketsueki"},{"key":"5023_CR49","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.1996.14.4.1252","volume":"14","author":"WP Bowman","year":"1996","unstructured":"Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996;14:1252\u201361.","journal-title":"J Clin Oncol"},{"key":"5023_CR50","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.exphem.2013.03.004","volume":"41","author":"M Kawasoe","year":"2013","unstructured":"Kawasoe M, Yamamoto Y, Okawa K, Funato T, Takeda M, Hara T, et al. Acquired resistance of leukemic cells to AraC is associated with the upregulation of aldehyde dehydrogenase 1 family member A2. Exp Hematol. 2013;41:597\u2013603. e2.","journal-title":"Exp Hematol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05023-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05023-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T10:42:10Z","timestamp":1700822530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05023-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["5023"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05023-0","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"30 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the institutional ethical review boards of the First Hospital of Nanchang (KY2021066). All animal experiments were performed following animal use guidelines and ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"590"}}